Interim report January-September 2008

Interim report January-September 2008

Continued strong growth in sales, profitability and cash flow from operating
activities

• Sales increased by 17 percent to SEK 166.1 (141.4) million. Calculated in
local sales currencies growth was 19 percent. During the third quarter sales
amounted to SEK 50.9 (44.6) million, corresponding to an increase of 14 percent.
Calculated in local sales currencies growth was 15 percent. During the third
quarter a particularly large increase was noted for fertility products in
Europe, 25 percent, which is Vitrolife's largest region in terms of sales.

• Gross income increased by 18 percent to SEK 115.1 (97.5) million, the gross
margin was 69 percent (69). Gross income for the third quarter increased by 15
percent to SEK 35.2 (30.5) million and the gross margin was 69 (68) percent.

• Operating income increased by 21 percent and amounted to SEK 21.7 (17.9)
million, which gives an operating margin of 13 (13) percent. For the third
quarter operating income increased by 24 percent and amounted to SEK 5.1 (4.1)
million.

• Operating income before research and development costs increased by 19 percent
to SEK 44.5 (37.5) million. This corresponds to a margin of 27 (27) percent. For
the third quarter the increase was 20 percent to SEK 12.6 (10.5) million.

• Consolidated net income increased by 25 percent adjusted for last year's
capitalization of the deferred tax asset in loss carry-forward for tax purposes
to the tune of SEK 12.3 million. Net income was SEK 20.0 (28.2) million, which
gives earnings per share of SEK 1.01 (1.42). For the third quarter net income
was SEK 5.9 (7.7) million and earnings per share were SEK 0.30 (0.39). Last
year's figure includes capitalization of a deferred tax asset in loss
carry-forward for tax purposes to the tune of SEK 4.1 million.

• The equity/assets ratio amounted to 84 percent (83).

• The cash flow from operating activities increased by 50 percent and amounted
to SEK 27.1 (18.0) million. The cash flow for the third quarter was SEK 5.8
(5.6) million. 

• Acquisition of a further 9 percent of the Italian subsidiary A.T.S., according
to plan.

• Investment in a new, more efficient, production facility in Gothenburg.

• Buying back of the company's own shares during the period. 

• New unique needle, Swemed Sense™, launched and approved for sales in Europe. 

• First lung transplantation outside Sweden using Steen Solution™ carried out. 

• Approval given for a clinical study on STEEN Solution™ in Canada, which will
form the basis of the application for sales approval in the USA and Canada. 

• The first three transplantations in Canada were carried out at the end of the
period.


October 22, 2008
Kungsbacka, Sweden 

Magnus Nilsson		
CEO

Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 140 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share
is listed on the OMX Nordic Exchange Stockholm's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

The information in this press release is such as that which Vitrolife is
required to publish in accordance with the Securities Exchange and Clearing
Operations Act. The information was submitted for publication on October 22,
2008 at 11.00 am.

This is a translation of the Swedish version of the interim report. When in
doubt, the Swedish wording prevails.